News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
London, UK, Solana Beach, California, and Ahmedabad, India – August 11, 2026 – Mereo BioPharma Group plc (Nasdaq: MREO), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026
London, June 2, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on Thursday, June 4, 2026, at 9:55 EDT/ 14:55 BST.
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
NOVATO, Calif., July 9, 2025 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis consistent with the original plan, around the end of the year.
Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available in fourth quarter 2019 A call for analysts and investors will take place at 1pm
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2025
London, May 29, 2025 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on Wednesday, June 4, 2025, at 17:30 EDT/ 22:30 BST.
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
London, May 13, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights.
Mereo BioPharma to Participate in Fireside Chat at the Needham Virtual Healthcare Conference
London, April 4, 2025 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 9:30 ET / 14:30 BST.
Mereo BioPharma Reports Full Year 2024 Financial results and Provides Corporate Highlights
London, March 26, 2025 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights.
Mereo BioPharma Provides Update on Lead Clinical Programs
London, January 12, 2025 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, setrusumab, a monoclonal antibody in Phase 3 clinical development for the treatment of Osteogenesis Imperfecta (OI) through a partnership with Ultragenyx Pharmaceutical, Inc. (Ultragenyx) and alvelestat, an oral neutrophil elastase inhibitor being studied for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The Company also reiterated its previous cash runway guidance that its current cash and cash equivalents are expected to fund operations into 2027, through multiple key inflection points.
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
London, January 7, 2025 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 8:15am PT / 04:15pm GMT.
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
London, November 12, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $80.5 million as of September 30, 2024, which the Company believes will provide runway into 2027, through multiple key inflection points.
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
NOVATO, Calif., October 7, 2024 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for setrusumab (UX143) as a treatment to reduce the risk of fracture associated with osteogenesis imperfecta (OI) Type I, III, or IV in patients 2 years of age and older.
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
London, August 13, 2024 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company’s $50 million registered direct offering in June 2024. Mereo expects that this will provide cash runway into 2027, through multiple key inflection points.
Dr Denise Scots-Knight Speaks to Biotech TV
Denise Scots-Knight talks to Amy Brown at Biotech TV about progress in our clinical programs.
